A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune ...

The field of cancer immunology has witnessed dramatic progress with the advent of immunotherapies targeting the tumor immune microenvironment (TIME).

BATF2 is a new type of tumor suppressor that can be epigenetically silenced by high levels of glutamine in the tumor microenvironment Glutamine silences BATF2 and leads to a weakened immune response ...

The tumor microenvironment is a battleground where infiltrating immune cells either subdue or promote a cancer, all while cancer cells try to dampen the body’s defenses. 1,2 Scientists have studied ...

A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL). The authors explained that while molecularly targeted therapies like Bruton ...

The tumor microenvironment is not just a site of cancer growth—it is a high-stakes metabolic contest where tumor and immune cells vie for limited resources. Amino acids, once seen as passive nutrients ...

On the one hand, circadian rhythm disorder contributes to tumor growth and metastasis by influencing the dysregulation of gene expression affecting the tumor itself. On the other hand, circadian ...